Loading…
World's largest vitamin producer, making vitamins, nutrition additives, fragrances and specialty chemicals.
World's largest vitamin producer, making vitamins, nutrition additives, fragrances and specialty chemicals.
Sells vitamins and feed additives as commodity chemicals, so earnings follow the price of vitamins A and E, set among a few global producers, and its cost edge. Methionine, an amino acid fed to livestock, is a newer large line. The Hu family founded and controls it.
In one line: China's DSM-Firmenich for vitamins/nutrition.
Moat: narrow (scale, cost advantage). Among the world's lowest-cost, largest-scale vitamin producers, squeezing higher-cost Western rivals.
Headquarters: Xinchang, Zhejiang, China · Founded: 1999 · Employees: 11,508
Size Zhejiang NHU (002001.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $12.3B, the 199th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥26.76 on 6 Nov 2026.
Performance Over six months the shares fell 23.1%, against +3.6% for the median peer and -16.4% for the China market (cap-weighted) — 2nd lowest of 10 in its peer set.
Growth Revenue grew 10.6% over the last twelve months (peer median +10.1%); the operating margin is 33.3% (peer median 21.1%).
Valuation It trades at 9.9× forward earnings against a peer median of 20.9× (2nd cheapest of 8).
Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -24 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 16.9 points above its cost of capital (6.2% WACC).
Next results Next results expected around 22 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥24.8B | CN¥22.1B | CN¥21.5B | CN¥15.1B | CN¥15.9B |
| Revenue growth | — | +3% | +43% | -5% | — |
| Gross profit | CN¥12.5B | CN¥9.58B | CN¥8.69B | CN¥4.73B | CN¥5.66B |
| EBITDA | n/a | CN¥9.85B | CN¥9.15B | CN¥4.72B | CN¥5.51B |
| Net income | CN¥7.31B | CN¥6.76B | CN¥5.87B | CN¥2.70B | CN¥3.62B |
| Free cash flow | CN¥6.07B | CN¥6.98B | CN¥5.51B | CN¥737M | -CN¥512M |
| Capital expenditure | CN¥2.43B | CN¥1.90B | CN¥1.60B | CN¥4.45B | CN¥4.93B |
| Total debt | CN¥7.61B | CN¥8.10B | CN¥9.12B | CN¥9.98B | CN¥10.4B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zhejiang NHU 002001.SZ | $12.3B | -23% | +11% | 33% | 9.9× | -7.8% |
| DSM-Firmenich DSFIR.AS | $29.5B | +62% | -45% | 8% | 30.1× | 24.3% |
| Basf BAS.DE | $52.6B | +2% | -4% | 7% | 16.8× | 5.7% |
| Zhejiang Medicine 600216.SS | $1.61B | -23% | -6% | 7% | 11.3× | -6.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002001.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.7% | +6.3% | 3rd lowest of 10 |
| 6-month return | -23.1% | +3.6% | 2nd lowest of 10 |
| Distance from 52-week high | -33.4% | -14.3% | 2nd lowest of 10 |
| Revenue growth (TTM) | +10.6% | +10.1% | 4th highest of 8 |
| Operating margin | 33.3% | 21.1% | highest of 8 |
| Forward P/E | 9.9× | 20.9× | 2nd cheapest of 8 |
| Growth the price implies (Req g, 7 yrs) | -7.8% | 8.8% | 2nd least demanding of 8 |
| Growth delivered (Del g) | +16.7% | +6.3% | highest of 8 |
| Hurdle (Req g minus delivered) | -24.5 pp | -1.0 pp | least demanding of 8 |
| ROIC minus cost of capital | +16.9 pp | +6.5 pp | 2nd highest of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang NHU 002001.SZ | China | $12.3B | -23% | +11% | 33% | 9.9× | -7.8% | +16.7% |
| Cipla CIPLA.NS | India | $12.1B | +4% | -1% | 13% | 29.0× | 28.2% | +8.1% |
| Aurobindo Pharma AUROPHARMA.NS | India | $10.9B | +22% | +14% | 15% | 22.4× | 21.0% | +6.3% |
| Lupin LUPIN.NS | India | $9.65B | -19% | +24% | 24% | 20.9× | 8.8% | +13.0% |
| Abivax ABVX.PA | France | $7.58B | -25% | n/a | n/a | n/a | n/a | n/a |
| Dong-E-E-Jiao 000423.SZ | China | $4.80B | -8% | +8% | 29% | 17.1× | -4.6% | +14.5% |
| Shijiazhuang Yiling Pharmaceutical 002603.SZ | China | $4.02B | -6% | +32% | 21% | 18.1× | -3.2% | -2.2% |
| Revolution Medicines RVMD | United States | $41.2B | +36% | n/a | n/a | n/a | n/a | n/a |
| Guangdong Zhongsheng Pharmaceutical 002317.SZ | China | $3.13B | +35% | -14% | 9% | 80.3× | 34.7% | +5.9% |
| Bausch Health Companies BHC.TO | Canada | $3.09B | +48% | +10% | 27% | 1.9× | -14.5% | +5.9% |